Product nameAnti-PLCL1 antibody [EPR11213]
See all PLCL1 primary antibodies
DescriptionRabbit monoclonal [EPR11213] to PLCL1
Tested applicationsSuitable for: WB, Flow Cyt, ICC/IF, IPmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Human
Recombinant fragment corresponding to Human PLCL1.
- Jurkat cell lysate; fetal brain, fetal kidney and fetal lung cell lysates; Jurkat cells.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab157200 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Predicted molecular weight: 123 kDa.|
|Flow Cyt||1/100 - 1/500.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
|ICC/IF||1/100 - 1/250.|
|IP||1/10 - 1/100.|
FunctionInvolved in an inositol phospholipid-based intracellular signaling cascade. Shows no PLC activity to phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol. Component in the phospho-dependent endocytosis process of GABA A receptor (By similarity). Regulates the turnover of receptors and thus contributes to the maintenance of GABA-mediated synaptic inhibition. Its aberrant expression could contribute to the genesis and progression of lung carcinoma. Acts as a inhibitor of PPP1C.
Tissue specificityExpressed in a variety of fetal and adult organs including brain, lung and kidney. Its expression was greatly reduced in small and non-small cell lung carcinoma. Isoform 1 is predominantly expressed in brain.
Sequence similaritiesContains 1 C2 domain.
Contains 1 PH domain.
Contains 1 PI-PLC X-box domain.
Contains 1 PI-PLC Y-box domain.
modificationsPhosphorylated by the catalytic subunit of PKA. Phosphorylation of Thr-93 resulted in dissociation of PPP1C from PRIP1.
- Information by UniProt
- Inactive phospholipase C-like protein 1 antibody
- Inactive protein 1 antibody
- Phospholipase C deleted in lung carcinoma antibody
Western blot analysis of Immunoprecipitation pellet from Human fetal brain lysate showing PLCL1, using ab157200 at 1/10 dilution for IP.
All lanes : Anti-PLCL1 antibody [EPR11213] (ab157200) at 1/10000 dilution
Lane 1 : Human fetal brain lysate
Lane 2 : Human fetal kidney lysate
Lane 3 : Human fetal lung lysate
Lane 4 : Jurkat lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 123 kDa
Immunofluorescence analysis of Jurkat cells, labeling PLCL1 using ab157200 at a 1/100 dilution.
Flow cytometry analysis of permeabilized Jurkat cells labeling PLCL1 (red), using ab157200 at a 1/100 dilution, and negative control cells probed with a Rabbit IgG (green)
ab157200 has been referenced in 1 publication.
- Xiong Z et al. Tumor Cell "Slimming" Regulates Tumor Progression through PLCL1/UCP1-Mediated Lipid Browning. Adv Sci (Weinh) 6:1801862 (2019). PubMed: 31131187